4D Medical’s share raising closes oversubscribed
4D Medical raises $8.4 million in an oversubscribed share purchase plan With Opthea shares suspended, investors rough up other phase III stage biotechs Immutep doses first patient in its phase III lung cancer trial Retail investors can respond …